Association Between CD30 Expression and EBV-DNA Detection Status With ABVD Chemotherapy Response in Classical Hodgkin Lymphoma Patients

DOI

10.2991/ahsr.k.210115.010How to use a DOI?

Keywords

“CD30”, “EBV”, “ABVD”, “Classical Hodgkin Lymphoma”

Abstract

CD30 is expressed in Hodgkin lymphoma (HL). To date, research efforts have focused on understanding its contribution to lymphomagenesis through anti-apoptotic mechanisms, and its effect on cell survival. It has been suggested that Epstein-Barr virus (EBV) plays a role in the pathogenesis of positive cases, as an early event in HL development. The presence of EBV is associated with prognosis. More than 40% of Hodgkin lymphoma (HL) patients are chemoresistant and show early relapse. The purpose of this study is to determine if there is an association between CD30 and EBV-DNA in HL with doxorubicin, bleomycin, vinblastine and dacarbazine (ABVD) regimen response therapies. This study is a cross-sectional study that was conducted at 3 hospitals in Bandung, Indonesia. We analyzed paraffin sections from 60 cases with histologically diagnosed with Classical Hodgkin lymphoma. ABVD chemotherapy response was evaluated by RECIL criteria. Detection of EBV-DNA by Real-Time PCR and CD30 expression using immunohistochemistry with semiquantitative evaluation was performed on all samples. All data were analyzed using a Chi-Square test with a p-value <0.05 for significant levels. From 60 cases, 28 cases (46,7%) showed a complete/partial response and 32 cases (53,3% showed no response to the ABVD regimen. EBV-DNA were present in 33 cases (55%), 10 cases from the complete/partial response group and 23 cases from the no response group. Low CD30 expression distribution (≤25%) dominated the complete response group (68%), whereas high CD30 distribution (>25%) dominated the nonresponse group (68,7%). The results showed a statistically significant EBV-DNA detection status (p=0.005) and CD30 expression (p=0.009) between the complete/partial response and nonresponse groups. In conclusion, the ABVD chemotherapy response of CHL is associated with CD30 expression and EBV-DNA infection.

Copyright

© 2021, the Authors. Published by Atlantis Press.

Open Access

This is an open access article distributed under the CC BY-NC license (http://creativecommons.org/licenses/by-nc/4.0/).

Download article (PDF)

TY  - CONF
AU  - Bethy S Hernowo
AU  - Hermin A Usman
AU  - Zahra Nurusshofa
AU  - Etis Primastari
AU  - Aryanti
PY  - 2021
DA  - 2021/01/16
TI  - Association Between CD30 Expression and EBV-DNA Detection Status With ABVD Chemotherapy Response in Classical Hodgkin Lymphoma Patients
BT  - Proceedings of the 4th International Conference on Sustainable Innovation 2020–Health Science and Nursing (ICoSIHSN 2020)
PB  - Atlantis Press
SP  - 48
EP  - 53
SN  - 2468-5739
UR  - https://doi.org/10.2991/ahsr.k.210115.010
DO  - 10.2991/ahsr.k.210115.010
ID  - Hernowo2021
ER  -